Minoxidil is highly toxic to cats and can be fatal with minimal exposure. Users suggest switching to oral minoxidil or taking precautions to prevent pet exposure.
Minoxidil is highly toxic to pets, especially cats and dogs, even in small amounts. Many users have switched to oral minoxidil to prevent accidental exposure to their pets.
A user experiencing hair loss despite using finasteride, minoxidil, and tretinoin. They're considering trying dutasteride or shaving their head if the situation doesn't improve.
Microneedling with finasteride, minoxidil, DMSO, and black seed oil shows mixed hair regrowth results. There are concerns about DMSO's safety and effectiveness.
The user is using topical minoxidil and oral finasteride for hair regrowth, with plans for a future hair transplant. They are considering additional treatments like dermastamping and exploring options for dutasteride, which is unavailable in their country.
A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.
A user discusses their experience with hair loss and treatments, including minoxidil, micro needling, rosemary oil, dietary supplements, and topical finasteride (Morr-F). They emphasize the impact of lifestyle on hair health and express hope for improvement with the new treatment.
Minoxidil is highly toxic to pets, particularly cats and dogs, and there is a call for proper labeling to warn pet owners. Despite some skepticism about the effectiveness of petitions, many agree that awareness and caution are necessary to prevent accidental poisoning.
Minoxidil is highly toxic to pets, and there is a call for manufacturers to add a "Toxic to Pets" warning on packaging. A petition has been started to raise awareness and prevent pet fatalities.
The user is seeking advice on safe hair loss treatments for a household with pets, avoiding minoxidil due to its danger to cats. They are considering alternatives like dutasteride and looking for affordable options.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
A user shared a tragic experience where their cat died after being exposed to Minoxidil, warning others of its toxicity to pets. Some users discussed switching to oral hair loss treatments, while others expressed condolences and shared their own concerns and experiences with topical treatments around pets.
A user applied minoxidil for hair loss and worried about its toxicity to cats after their cat drank from a water fountain they touched. After consulting a vet and pet poison control, they were reassured that the exposure was not enough to harm the cat, and others advised using gloves and being cautious in the future.
Minoxidil is highly toxic to cats and dogs, even in small amounts. Users suggest switching to oral minoxidil or taking precautions to prevent pet exposure.
Minoxidil is harmful to pets, especially cats, if they contact it. Users recommend switching to oral minoxidil or taking precautions like washing hands and using head coverings to prevent exposure.
In this conversation, people discussed how Minoxidil and Finasteride can be toxic to cats if ingested. It was highlighted that even when being careful with application, there is still a risk of poisoning due to the potential for contact between fur/hair and the substances.
Minoxidil is toxic to cats, so users should wash hands after application and ensure it dries before pets are near. Some switch to oral minoxidil to avoid risks, while others use topical forms cautiously.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
Minoxidil is extremely toxic to cats, even from residue on surfaces, and can be deadly if they come into contact with it. Switching to oral minoxidil is suggested as a safer alternative for pet owners.
Minoxidil is extremely toxic to cats, even in small amounts, and can be fatal. Switching to oral minoxidil is safer for cat owners, but precautions should still be taken to prevent exposure.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
Minoxidil is highly toxic to cats, and even small amounts can be fatal. The user decided against using topical minoxidil due to the risk to their cats and considered oral minoxidil and ketoconazole shampoo as alternatives.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
The conversation is a satirical discussion about hair loss treatments, jokingly suggesting using a Cocker Spaniel as an alternative to actual treatments like finasteride, minoxidil, RU58841, ketoconazole, and dermarolling.
Eucapill 2% used for 1 month reduced shedding from 200 to 10/20 hairs daily with no side effects. Finasteride caused side effects like ED and watery semen.
Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.